Literature DB >> 28405317

Changes in gene expression of neo-squamous mucosa after endoscopic treatment for dysplastic Barrett's esophagus and intramucosal adenocarcinoma.

Angelique Levert-Mignon1, Michael J Bourke2, Sarah J Lord3, Andrew C Taylor4, Antony R Wettstein5, Melanie Edwards6, Natalia K Botelho1, Rebecca Sonson2, Chatura Jayasekera4, Oliver M Fisher1, Melissa L Thomas3, Finlay Macrae7, Damian J Hussey8, David I Watson8, Reginald V Lord9.   

Abstract

BACKGROUND: Endoscopic therapy, including by radiofrequency ablation (RFA) or endoscopic mucosal resection (EMR), is first line treatment for Barrett's esophagus (BE) with high-grade dysplasia (HGD) or intramucosal cancer (IMC) and may be appropriate for some patients with low-grade dysplasia (LGD).
OBJECTIVE: The purpose of this study was to investigate the molecular effects of endotherapy.
METHODS: mRNA expression of 16 genes significantly associated with different BE stages was measured in paired pre-treatment BE tissues and post-treatment neo-squamous biopsies from 36 patients treated by RFA (19 patients, 3 IMC, 4 HGD, 12 LGD) or EMR (17 patients, 4 IMC, 13 HGD). EMR was performed prior to RFA in eight patients. Normal squamous esophageal tissues were from 20 control individuals.
RESULTS: Endoscopic therapy resulted in significant change towards the normal squamous expression profile for all genes. The neo-squamous expression profile was significantly different to the normal control profile for 11 of 16 genes.
CONCLUSION: Endotherapy results in marked changes in mRNA expression, with replacement of the disordered BE dysplasia or IMC profile with a more "normal" profile. The neo-squamous mucosa was significantly different to the normal control squamous mucosa for most genes. The significance of this finding is uncertain but it may support continued endoscopic surveillance after successful endotherapy.

Entities:  

Keywords:  Barrett’s esophagus; endoscopic mucosal resection; esophageal adenocarcinoma; esophageal neoplasms; high-grade dysplasia; radiofrequency ablation

Year:  2016        PMID: 28405317      PMCID: PMC5384557          DOI: 10.1177/2050640616650794

Source DB:  PubMed          Journal:  United European Gastroenterol J        ISSN: 2050-6406            Impact factor:   4.623


  35 in total

1.  Durability of radiofrequency ablation in Barrett's esophagus with dysplasia.

Authors:  Nicholas J Shaheen; Bergein F Overholt; Richard E Sampliner; Herbert C Wolfsen; Kenneth K Wang; David E Fleischer; Virender K Sharma; Glenn M Eisen; M Brian Fennerty; John G Hunter; Mary P Bronner; John R Goldblum; Ana E Bennett; Hiroshi Mashimo; Richard I Rothstein; Stuart R Gordon; Steven A Edmundowicz; Ryan D Madanick; Anne F Peery; V Raman Muthusamy; Kenneth J Chang; Michael B Kimmey; Stuart J Spechler; Ali A Siddiqui; Rhonda F Souza; Anthony Infantolino; John A Dumot; Gary W Falk; Joseph A Galanko; Blair A Jobe; Robert H Hawes; Brenda J Hoffman; Prateek Sharma; Amitabh Chak; Charles J Lightdale
Journal:  Gastroenterology       Date:  2011-05-06       Impact factor: 22.682

2.  Comparison of COX-2, Ki-67, and BCL-2 expression in normal esophageal mucosa, Barrett's esophagus, dysplasia, and adenocarcinoma with postablation mucosa and implications for ablative therapies.

Authors:  Christopher John Lewis; Sri Ganeshamurthy Thrumurthy; Susan Pritchard; Gordon Armstrong; Stephen Edwin Arthur Attwood
Journal:  Surg Endosc       Date:  2011-02-27       Impact factor: 4.584

Review 3.  Molecular biomarkers and ablative therapies for Barrett's esophagus.

Authors:  Jacob A Chisholm; George C Mayne; Damian J Hussey; David I Watson
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2012-09       Impact factor: 3.869

4.  Remission of Barrett's esophagus with early neoplasia 5 years after radiofrequency ablation with endoscopic resection: a Netherlands cohort study.

Authors:  K Nadine Phoa; Roos E Pouw; Frederike G I van Vilsteren; Carine M T Sondermeijer; Fiebo J W Ten Kate; Mike Visser; Sybren L Meijer; Mark I van Berge Henegouwen; Bas L A M Weusten; Erik J Schoon; Rosalie C Mallant-Hent; Jacques J G H M Bergman
Journal:  Gastroenterology       Date:  2013-03-28       Impact factor: 22.682

5.  Increased risk for persistent intestinal metaplasia in patients with Barrett's esophagus and uncontrolled reflux exposure before radiofrequency ablation.

Authors:  Kumar Krishnan; John E Pandolfino; Peter J Kahrilas; Laurie Keefer; Lubomyr Boris; Srinadh Komanduri
Journal:  Gastroenterology       Date:  2012-05-15       Impact factor: 22.682

6.  Multimodality endoscopic eradication for neoplastic Barrett oesophagus: results of an European multicentre study (EURO-II).

Authors:  K Nadine Phoa; Roos E Pouw; Raf Bisschops; Oliver Pech; Krish Ragunath; Bas L A M Weusten; Brigitte Schumacher; Bjorn Rembacken; Alexander Meining; Helmut Messmann; Erik J Schoon; Liebwin Gossner; Jayan Mannath; C A Seldenrijk; Mike Visser; Toni Lerut; Stefan Seewald; Fiebo J ten Kate; Christian Ell; Horst Neuhaus; Jacques J G H M Bergman
Journal:  Gut       Date:  2015-03-02       Impact factor: 23.059

7.  Detection of intestinal metaplasia after successful eradication of Barrett's Esophagus with radiofrequency ablation.

Authors:  Benjamin J Vaccaro; Susana Gonzalez; John M Poneros; Peter D Stevens; Kristina M Capiak; Charles J Lightdale; Julian A Abrams
Journal:  Dig Dis Sci       Date:  2011-04-06       Impact factor: 3.199

8.  Intestinal metaplasia recurs infrequently in patients successfully treated for Barrett's esophagus with radiofrequency ablation.

Authors:  Eric S Orman; Hannah P Kim; William J Bulsiewicz; Cary C Cotton; Evan S Dellon; Melissa B Spacek; Xiaoxin Chen; Ryan D Madanick; Sarina Pasricha; Nicholas J Shaheen
Journal:  Am J Gastroenterol       Date:  2012-12-18       Impact factor: 10.864

9.  ACG Clinical Guideline: Diagnosis and Management of Barrett's Esophagus.

Authors:  Nicholas J Shaheen; Gary W Falk; Prasad G Iyer; Lauren B Gerson
Journal:  Am J Gastroenterol       Date:  2015-11-03       Impact factor: 10.864

10.  British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus.

Authors:  Rebecca C Fitzgerald; Massimiliano di Pietro; Krish Ragunath; Yeng Ang; Jin-Yong Kang; Peter Watson; Nigel Trudgill; Praful Patel; Philip V Kaye; Scott Sanders; Maria O'Donovan; Elizabeth Bird-Lieberman; Pradeep Bhandari; Janusz A Jankowski; Stephen Attwood; Simon L Parsons; Duncan Loft; Jesper Lagergren; Paul Moayyedi; Georgios Lyratzopoulos; John de Caestecker
Journal:  Gut       Date:  2013-10-28       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.